Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06489873 · ClinicalTrials.gov registry record · NA
Lutein, Zeaxathin, and Fish Oil Supplementation
A NA study of Age-related Macular Degeneration and Bone Loss, sponsored by Texas A&M University.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06489873: Recruiting NA study of Age-related Macular Degeneration and Bone Loss, sponsored by Texas A&M University.
NCT06489873 is a NA study of Age-related Macular Degeneration and Bone Loss that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 80 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06489873, a NA study of Age-related Macular Degeneration and Bone Loss, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months? Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation. Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density. Participants will be asked to take either a LZF supplement or placebo daily for 6 months.
Primary Outcome
The MPS II will be used to measure MPOD
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo Comparator
- DIETARY_SUPPLEMENT Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)
Study Locations (1)
Texas
- Gilchrist Building - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2026-05-01 |
| Phase | NA |
What NCT06489873 shows while recruiting
NCT06489873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT06489873 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06489873 about?
NCT06489873 is a clinical study titled "Lutein, Zeaxathin, and Fish Oil Supplementation". The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to c...
What is the current status of trial NCT06489873?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-02-07. Estimated completion is 2026-05-01.
What conditions does trial NCT06489873 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Bone Loss, Cognitive Performance.
What interventions are being tested in trial NCT06489873?
The interventions under investigation include: Placebo Comparator (DIETARY_SUPPLEMENT), Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06489873?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06489873 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06489873's enrollment target sits among peer trials
80 37th of 74 higher than 38 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
-
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI